Your browser doesn't support javascript.
loading
Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128].
Gogas, Helen; Dummer, Reinhard; Ascierto, Paolo A; Arance, Ana; Mandalà, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsová, Ivana; Gutzmer, Ralf; Chiarion Sileni, Vanna; Dutriaux, Caroline; Yamazaki, Naoya; Loquai, Carmen; Queirolo, Paola; de Willem, Groot J; Sellier, Abir T; Suissa, Jeanne; Murris, Juliette; Gollerkeri, Ashwin; Robert, Caroline; Flaherty, Keith T.
Afiliación
  • Gogas H; National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece. Electronic address: helgogas@gmail.com.
  • Dummer R; University Hospital Zürich Skin Cancer Center, Zürich, Switzerland.
  • Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
  • Arance A; Hospital Clinic of Barcelona, Barcelona, Spain.
  • Mandalà M; Unit of Medical Oncology, University of Perugia, Perugia, Italy.
  • Liszkay G; National Institute of Oncology, Budapest, Hungary.
  • Garbe C; Eberhard Karls University, Tuebingen, Germany.
  • Schadendorf D; University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.
  • Krajsová I; University Hospital Prague and Charles University First Medical Faculty, Prague, Czech Republic.
  • Gutzmer R; Hannover Medical School, Hannover, Germany.
  • Chiarion Sileni V; Oncology Institute of Veneto IRCCS, Padua, Italy.
  • Dutriaux C; University Hospital Centre Bordeaux, Hôpital Saint-Andre´, Bordeaux, France.
  • Yamazaki N; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Loquai C; University Medical Center, Mainz, Germany.
  • Queirolo P; Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy; Ospedale Policlinico San Martino IRCCS, Genoa, Italy.
  • de Willem GJ; Department of Medical Oncology, Isala Oncological Center, Zwolle, Netherlands.
  • Sellier AT; Pierre Fabre Medicament, Boulogne-Billancourt, France.
  • Suissa J; Pierre Fabre Medicament, Boulogne-Billancourt, France.
  • Murris J; Pierre Fabre Medicament, Boulogne-Billancourt, France.
  • Gollerkeri A; At Time of Research: Pfizer Inc., Boulder, CO, USA.
  • Robert C; Institute Gustave Roussy, Villejuif, France.
  • Flaherty KT; Massachusetts General Hospital, Boston, MA, USA.
Eur J Cancer ; 160: 287-288, 2022 Jan.
Article en En | MEDLINE | ID: mdl-34756500
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Aspecto: Patient_preference Idioma: En Revista: Eur J Cancer Año: 2022 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Aspecto: Patient_preference Idioma: En Revista: Eur J Cancer Año: 2022 Tipo del documento: Article